Overview

Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients

Status:
COMPLETED
Trial end date:
2025-01-08
Target enrollment:
Participant gender:
Summary
68Ga-NYM005 is a CAIX-targeting small-molecular radiotracer for PET/CT imaging of clear cell renal cell carcinoma
Phase:
PHASE1
Details
Lead Sponsor:
Norroy Bioscience Co., LTD